ICI-63197

ICI-63197

0ICI-63197 is a pharmacological compound developed by ICI, a British chemical company. It is a member of the benzodiazepine class of drugs, which are commonly used for their sedative and anxiolytic effects.

History

ICI-63197 was first synthesized in the laboratories of ICI in the late 20th century. The compound was part of a series of benzodiazepines developed by the company, which also includes well-known drugs such as diazepam and lorazepam.

Pharmacology

As a benzodiazepine, ICI-63197 acts on the GABA receptors in the brain. These receptors are responsible for inhibitory neurotransmission, and their activation leads to a decrease in neuronal excitability. This results in the sedative and anxiolytic effects characteristic of this class of drugs.

Clinical Use

The clinical use of ICI-63197 is not well-documented, as it is not a commonly prescribed drug. However, like other benzodiazepines, it may be used in the treatment of conditions such as anxiety disorders, insomnia, and seizure disorders.

Side Effects

Potential side effects of ICI-63197 are similar to those of other benzodiazepines and may include drowsiness, dizziness, and dependency with long-term use.

See Also

• Benzodiazepine
• GABA receptor
• Imperial Chemical Industries

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!